UAE: Global pharmaceutical company Takeda announced today a new Area Head for the Near East, Middle East & Africa (NEMEA) operations. Takafumi Horii (Taka) has been appointed to the new position after his nine years journey at Takeda holding a number of strategic and leadership roles in many countries. The appointment is effective as of 17th, September, 2018.

Based out of Dubai, Taka’s new role will see him spearhead Takeda’s continued growth across the NEMEA region, while upholding the organization’s unwavering commitment to serving patients and its long-held reputation as a best employer.

Taka joined Takeda Japan in 2009 as Corporate Strategy & Planning Manager before relocating to Takeda China as Head of Strategic Planning in 2011. A move to Head of Strategic Projects & Planning for North Asia followed, before he joined the EM BU as Vice President, Strategy & Business Support in 2015.

In his most recent role as President & General Manager Taiwan, which he held in 2016, Taka oversaw the successful launch of new pharmaceutical products including Adcetris and Entyvio. He also cultivated a culture that saw Takeda Taiwan named Taiwan's Best Companies to Work for in Asia, alongside Top Employer® status in 2016 and 2017.

As Standing Director & Market Access Chair at International Research-based Pharmaceutical Manufacturers Associations (IRPMA) in Taiwan, he has also supported in healthcare policy improvements for patients and industry development in the past 2 years.

“2018 has seen Takeda take massive strides towards our ambition of becoming a global, values-based, R&D-driven biopharmaceutical leader, and the rapidly evolving NEMEA region is an integral part of this,” commented Taka Horii. “Leading our continued growth in the region is an exciting prospect, and I relish the opportunities and challenges that lay ahead for Takeda.” Added Taka.

“Taka has played a vital role in Takeda’s success in Asia during the past decade, showing superb leadership and intelligent strategic direction at every step,” commented Danilo Cassani, Takeda’s Emerging Markets Business Unit Functional Integration Team Lead and the Prior NEMEA Area Head. “The best practice he brings from Asia, alongside his deep knowledge of Takeda’s unique culture, will serve Taka extremely well as he helps lead our business into a new chapter.” Added Danilo.

-Ends-

About Takeda

Takeda Pharmaceutical Company Limited is a global, R&D-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines. Takeda focuses its research efforts on oncology, gastroenterology and central nervous system therapeutic areas. It also has specific development programs in specialty cardiovascular diseases as well as late-stage candidates for vaccines. Takeda conducts R&D both internally and with partners to stay at the leading edge of innovation. New innovative products, especially in oncology and gastroenterology, as well as its presence in emerging markets, fuel the growth of Takeda. More than 30,000 Takeda employees are committed to improving quality of life for patients, working with our partners in health care in more than 70 countries. For more information, visit http://www.takeda.com

© Press Release 2018

Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.

The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.

To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.